Hypothesis: When resveratrol is delivered via liposomes that bypass first‑pass metabolism, the resulting surge in hepatic NAD+ precedes any measurable rise in mitochondrial superoxide, allowing SIRT3 to deacetylate and activate key antioxidant enzymes (e.g., SOD2) before redox stress can impair sirtuin function. This temporal decoupling predicts a measurable interval—approximately 15–45 minutes post‑dose—during which NAD+/NADH ratios increase, SIRT3 activity rises, and mitochondrial ROS remains at baseline levels. If this window exists, then blocking NAD+ biosynthesis (e.g., with FK866) should abolish the early SIRT3 activation and the subsequent attenuation of ROS, whereas scavenging ROS after the window should not affect the initial SIRT3 spike.

Testable predictions:

1. In mice given liposomal resveratrol (dose achieving ~2000% bioavailability increase [2]), hepatic NAD+ will peak at 20 ± 5 minutes, as measured by luciferase‑based NAD+ assays, while mitochondrial superoxide (MitoSOX fluorescence) will not rise significantly until after 50 ± 10 minutes.
2. SIRT3 activity, assessed by immunoprecipitation of acetylated SOD2 followed by western blot, will show a significant increase at 30 minutes post‑dose, correlating with the NAD+ peak.
3. Pretreatment with the NAD+ biosynthesis inhibitor FK866 will eliminate both the early NAD+ rise and the SIRT3 activation at 30 minutes, but will not alter the later ROS increase observed at 60 minutes.
4. Administering a mitochondrial ROS scavenger (MitoTEMPO) after the NAD+ peak (e.g., at 45 minutes) will not further enhance SIRT3 activity beyond that seen with liposomal resveratrol alone, indicating that the early SIRT3 activation is ROS‑independent.

Experimental design: Use C57BL/6 mice divided into four groups (n=6 per group): (A) liposomal resveratrol, (B) liposomal resveratrol + FK866 (administered 15 minutes before resveratrol), (C) liposomal resveratrol + MitoTEMPO (given at 45 minutes), (D) control liposomal vehicle. Collect liver tissue at 0, 15, 30, 45, 60, and 90 minutes. Measure NAD+/NADH ratios, SIRT3 activity (via SOD2 deacetylation), and mitochondrial superoxide. Statistical analysis will employ two‑way ANOVA with post‑hoc Tukey tests.

Falsifiability: If NAD+ does not rise before ROS, or if SIRT3 activation coincides with or follows ROS elevation, the hypothesis is refuted. Similarly, if FK866 fails to blunt early SIRT3 activation despite lowering NAD+, the proposed NAD+‑first mechanism is invalid.

Novel mechanistic insight: Current models treat sirtuin activation and redox modulation as intertwined feedback loops [5]. By exploiting liposomes to achieve supra‑physiological hepatic resveratrol concentrations that saturate the NAD+ salvage pathway before oxidative metabolism can generate significant ROS, we create a kinetic bottleneck that isolates the enzymatic arm of sirtuin signaling. This approach directly addresses the open question of disentangling direct activation from ROS noise via NAD+ flux tracing [6] and extends the utility of advanced delivery systems beyond mere bioavailability enhancement to temporal pathway isolation.